Genomics BioSci & Tech. Co.Ltd.
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; reproductive health and cancer testing services; and contract development and manufacturing services. Genomics BioSci & Tech. Co.,Ltd. was founded in 2001 and is based in New Taipei City, Taiwan.
Genomics BioSci & Tech. Co.Ltd. (4195) - Total Assets
Latest total assets as of June 2024: NT$1.28 Billion TWD
Based on the latest financial reports, Genomics BioSci & Tech. Co.Ltd. (4195) holds total assets worth NT$1.28 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genomics BioSci & Tech. Co.Ltd. - Total Assets Trend (2019–2023)
This chart illustrates how Genomics BioSci & Tech. Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genomics BioSci & Tech. Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2023)
Genomics BioSci & Tech. Co.Ltd.'s total assets of NT$1.28 Billion consist of 41.6% current assets and 58.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 22.3% |
| Accounts Receivable | NT$140.69 Million | 12.4% |
| Inventory | NT$61.51 Million | 5.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.73 Million | 0.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Genomics BioSci & Tech. Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genomics BioSci & Tech. Co.Ltd.'s current assets represent 41.6% of total assets in 2023, a decrease from 60.6% in 2019.
- Cash Position: Cash and equivalents constituted 22.3% of total assets in 2023, down from 43.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Genomics BioSci & Tech. Co.Ltd. Competitors by Total Assets
Key competitors of Genomics BioSci & Tech. Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genomics BioSci & Tech. Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genomics BioSci & Tech. Co.Ltd. generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genomics BioSci & Tech. Co.Ltd. is currently not profitable relative to its asset base.
Genomics BioSci & Tech. Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.09 | 4.21 | 3.01 |
| Quick Ratio | 2.60 | 3.73 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$335.77 Million | NT$ 357.68 Million | NT$ 185.91 Million |
Genomics BioSci & Tech. Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Genomics BioSci & Tech. Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | NT$1.13 Billion |
| Market Capitalization | $38.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genomics BioSci & Tech. Co.Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Genomics BioSci & Tech. Co.Ltd.'s assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Genomics BioSci & Tech. Co.Ltd. (2019–2023)
The table below shows the annual total assets of Genomics BioSci & Tech. Co.Ltd. from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.13 Billion | +1.26% |
| 2022-12-31 | NT$1.12 Billion | +31.24% |
| 2021-12-31 | NT$853.18 Million | -26.15% |
| 2020-12-31 | NT$1.16 Billion | +26.35% |
| 2019-12-31 | NT$914.30 Million | -- |